Met receptor tyrosine kinase transactivation is involved in proteinase-activated receptor-2-mediated hepatocellular carcinoma cell invasion

Carcinogenesis

Volumn 30, Issue 9, 2009, Pages 1487-1496

  Kaufmann, Roland ^a   Oettel, Claudia ^a   Horn, Antje ^a   Halbhuber, Karl Jürgen ^a   Eitner, Annett ^a   Krieg, Reimar ^a   Katenkamp, Kathrin ^a   Henklein, Peter ^b   Westermann, Martin ^a   Böhmer, Frank D ^a   Ramachandran, Rithwik ^c   Saifeddine, Mahmoud ^c   Hollenberg, Morley D ^c   Settmacher, Utz ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; PROTEINASE ACTIVATED RECEPTOR 2; SCATTER FACTOR RECEPTOR; SMALL INTERFERING RNA; GROWTH FACTOR RECEPTOR; MET PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE; ONCOPROTEIN; REACTIVE OXYGEN METABOLITE;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL INVASION; CELL MEMBRANE; CONTROLLED STUDY; DOWN REGULATION; ELECTRON MICROSCOPY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOREACTIVITY; LIVER CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSACTIVATION; AMINO ACID SEQUENCE; CANCER INVASION; LIVER TUMOR; METABOLISM; MOLECULAR GENETICS; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

AMINO ACID SEQUENCE; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; LIVER NEOPLASMS; MOLECULAR SEQUENCE DATA; NEOPLASM INVASIVENESS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS; REACTIVE OXYGEN SPECIES; RECEPTOR, PAR-2; RECEPTORS, GROWTH FACTOR; TRANSCRIPTIONAL ACTIVATION;

EID: 70249123081     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgp153     Document Type: Article

References (51)

1. Ossovskaya,V.S. et al. (2004) Protease-activated receptors: contribution to physiology and disease. Physiol. Rev., 84, 579-621.
2. Steinhoff,M. et al. (2005) Proteinase-activated receptors: transducers of proteinase-mediated signaling in inflammation and immune response. Endocr. Rev., 26, 1-43.
3. Ramachandran,R. et al. (2008) Proteinases and signaling: pathophysiological and therapeutic implications via PARs and more. Br. J. Pharmacol. 153 (suppl. 1), S263-S282.
4. Vu,T.K. et al. (1991) Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell, 64, 1057-1068.
5. 2+ mobilization. FEBS Lett., 288, 123-128.
6. Ishihara,H. et al. (1997) Protease-activated receptor 3 is a second thrombin receptor in humans. Nature, 386, 502-506.
7. Xu,W.F. et al. (1998) Cloning and characterization of human proteaseactivated receptor 4. Proc. Natl Acad. Sci. USA, 95, 6642-6646.
8. Kahn,M.L. et al. (1998) A dual thrombin receptor system for platelet activation. Nature, 394, 690-694.
9. Nystedt,S. et al. (1994) Molecular cloning of a potential proteinase activated receptor. Proc. Natl Acad. Sci. USA, 91 9208-9212.
10. Camerer,E. (2007) Protease signaling in tumour progression. Thromb. Res. 120 (suppl. 2), S575-S581.
11. Even-Ram,S. et al. (1998) Thrombin receptor overexpression in malignant and physiological invasion processes. Nat. Med., 4 909-914.
12. Even-Ram,S.C. et al. (2001) Tumour cell invasion is promoted by activation of protease-activated receptor-1 in cooperation with avβ5 integrin. J. Biol. Chem., 276, 10952-10962.
13. Darmoul,D. et al. (2003) Aberrant expression and activation of the thrombin receptor protease-activated receptor-1 induce cell proliferation and motility in human colon cancer cells. Am. J. Pathol., 162, 1503-1513.
14. Bergmann,S. et al. (2006) PAR-type thrombin receptors in renal carcinoma cells: PAR1-mediated EGFR activation promotes cell migration. Oncol. Rep., 15, 889-893.
15. Avila,M.A. et al. (2006) New therapies for hepatocellular carcinoma. Oncogene, 25, 3866-3884.
16. Kaufmann,R. et al. (2007) Thrombin-mediated hepatocellular carcinoma cell migration: Cooperative action via proteinase-activated receptors 1 and 4. J. Cell. Physiol., 211, 699-707.
17. Kaneider,N.C. et al. (2007) 'Role reversal' for the receptor PAR1 in sepsisinduced vascular damage. Nat. Immunol., 8, 1303-1312.
18. Jikuhara,A. et al. (2003) MAP kinase-mediated proliferation of DLD-1 carcinoma by the stimulation of protease-activated receptor 2. Life Sci., 73, 2817-2829.
19. Darmoul,D. et al. (2004) Protease-activated receptor 2 in colon cancer: Trypsin-induced MAPK phosphorylation and cell proliferation are mediated by epidermal growth factor receptor transactivation. J. Biol. Chem., 279, 20927-20934.
20. Ge,L. et al. (2004) Constitutive protease-activated-receptor-2 mediated migration of MDA MB-231 breast cancer cells requires both b-arrestin-1 and 2. J. Biol. Chem., 279, 55419-55424.
21. Hjortoe,G.M. et al. (2004) Tissue factor-factor VIIa-specific up-regulation of IL-8 expression in MDA-MB231 cells is mediated by PAR-2 and results in increased cell migration. Blood, 103, 3029-3037.
22. Shi,X. et al. (2004) Protease-activated receptors (PAR1 and PAR2) contribute to tumour cell motility and metastasis. Mol. Cancer Res. 2, 395-402.
23. Shimamoto,R. et al. (2004) A role for protease-activated receptor-2 in pancreatic cancer cell proliferation. Int. J. Oncol. 24, 1401-1406.
24. Rattenholl,A. et al. (2007) Proteinase-activated receptor-2 (PAR2): A tumour suppressor in skin carcinogenesis. J. Invest. Dermatol., 127, 2245-2252.
25. Neaud,V. et al. (2000) Paradoxical pro-invasive effect of the serine proteinase inhibitor tissue factor pathway inhibitor-2 on human hepatocellular carcinoma cells. J. Biol. Chem., 275, 35565-35569.
26. Breuhahn,K. et al. (2006) Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene, 25, 3787-3800.
27. Han,C. et al. (2006) Prostaglandin E2 receptor EP1 transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells. J. Cell. Physiol., 207, 261-270.
28. Gentile,A. et al. (2008) The Met tyrosine kinase receptor in development and cancer. Cancer Metastasis Rev., 27, 85-94.
29. Kaufmann,R. et al. (2002) PAR-1- and PAR-3-type thrombin receptor expression in primary cultures of human renal cell carcinoma cells. Int. J. Oncol., 20, 177-180.
30. Nickel,T.J. et al. (2006) Constitutive expression of functionally active protease-activated receptors 1 and 2 in human conjunctival epithelial cells. Mediators Inflamm., 2006, 61359.
31. Kong,W. et al. (1997) Luminal trypsin may regulate enterocytes through proteinase-activated receptor 2. Proc. Natl Acad. Sci. USA 94, 8884-8889.
32. Al-Ani,B. et al. (1999) Proteinase-activated receptor 2 (PAR2): development of a ligand-binding assay correlating with activation of PAR2 by PAR1 and PAR2-derived peptide ligands. J. Pharmacol. Exp. Ther., 290, 753-760.
33. Krieg,R. et al. (2008) N, N-Dialkylaminostyryl dyes: Specific and highly fluorescent substrates of peroxidase and their application in histochemistry. J. Mol. Histol., 39, 169-191.
34. Albini,A. et al. (1987) A rapid in vitro assay for quantitating the invasive potential of tumour cells. Cancer Res., 47, 3239-3245.
35. Molino,M. et al. (1997) Endothelial cell thrombin receptors and PAR-2. Two protease-activated receptors located in a single cellular environment. J. Biol. Chem., 272, 11133-11141.
36. McGuire,J.J. et al. (2004) 2-furoyl-LIGRLO-amide: A potent and selective proteinase-activated receptor 2 agonist. J. Pharmacol. Exp. Ther., 309, 1124-1131.
37. Covic,L. et al. (2002) Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides. Proc. Natl Acad. Sci. USA, 99, 643-648.
38. Salvi,A. et al. (2007) In vitro c-met inhibition by antisense RNA and plasmid-based RNAi down-modulates migration and invasion of hepatocellular carcinoma cells. Int. J. Oncol., 31 451-460.
39. Birchmeier,C. et al. (2003) Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol., 4, 915-925.
40. Fischer,O. et al. (2004) Reactive oxygen species mediate Met receptor transactivation by G protein-coupled receptors and the epidermal growth factor receptor in human carcinoma cells. J. Biol. Chem., 279, 28970-28978.
41. Morris,D.R. et al. (2006) Protease-activated receptor-2 is essential for factor VIIa and Xa-induced signaling, migration, and invasion of breast cancer cells. Cancer Res., 66, 307-314.
42. Versteeg,H.H. et al. (2008) Inhibition of tissue factor signaling suppresses tumour growth. Blood, 111, 190-199.
43. Bohm,S.K. et al. (1996) Mechanisms of desensitization and resensitization of proteinase-activated receptor-2. J. Biol. Chem. 271, 22003-22016.
44. Stalheim,L. et al. (2005) Multiple independent functions of arrestins in regulation of protease-activated receptor-2 signaling and trafficking. Mol. Pharmacol., 67, 1-10.
45. Torii,S. et al. (2006) ERK MAP kinase in G cell cycle progression and cancer. Cancer Sci., 97, 697-702.
46. Albini,A. et al. (2007) The tumour microenvironment as a target for chemo-prevention. Nat. Rev. Cancer, 7, 139-147.
47. Borgoño,C.A. et al. (2004) The emerging roles of human tissue kallikreins in cancer. Nat. Rev. Cancer, 4, 876-890.
48. Oikonomopoulou,K. et al. (2006) Proteinase-activated receptors, targets for kallikrein signaling. J. Biol. Chem., 281, 32095-32112.
49. Hangan,D. et al. (1996) Integrin VLA-2 (α2β1) function in postextravasation movement of human rhabdomyosarcoma RD cells in the liver. Cancer Res., 56, 3142-3147.
50. Xie,Q. et al. (2001) SF/HGF-c-Met autocrine and paracrine promote metastasis of hepatocellular carcinoma. World J. Gastroenterol., 7, 816-820.
51. Peruzzi,B. et al. (2006) Targeting the c-Met signaling pathway in cancer. Clin. Cancer Res., 12, 3657-3660.